Examining how opioid treatments affect HIV persistence in people with HIV and opioid use disorders
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders
This study is looking at how medications like methadone and buprenorphine can help people living with HIV who also struggle with opioid use, focusing on how these treatments might affect their immune system and the virus itself, to find better ways to support their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10458790 on NIH RePORTER |
What this research studies
This research investigates the effects of medication-assisted therapies, such as methadone and buprenorphine, on HIV-1 persistence in individuals living with HIV who also have opioid use disorders. The study aims to understand how these treatments may influence immune responses and the reactivation of HIV-1. By conducting longitudinal studies, researchers will gather data on the biological impacts of these therapies on HIV latency and overall health outcomes for patients. The findings could provide valuable insights into optimizing treatment strategies for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are living with HIV and have a history of opioid use disorders.
Not a fit: Patients who do not have HIV or opioid use disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for individuals living with HIV and opioid use disorders, potentially enhancing their health outcomes.
How similar studies have performed: Previous research has shown that medication-assisted treatments can significantly reduce HIV incidence, indicating a promising avenue for further exploration in this area.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Springer, Sandra Ann — Yale University
- Study coordinator: Springer, Sandra Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.